Evaluation of risk management in a natalizumab home infusion procedure

Natalizumab is a well-established disease-modifying therapy used in active multiple sclerosis (MS). The most serious adverse event is progressive multifocal leukoencephalopathy. For safety reasons, hospital implementation is mandatory. The SARS-CoV-2 pandemic has deeply affected hospital practices l...

Descripción completa

Detalles Bibliográficos
Autores principales: Lafontaine, J.-C., Boucher, J., Giovannelli, J., Petit, J., Outteryck, O., Balagny, S., Zéphir, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186396/
https://www.ncbi.nlm.nih.gov/pubmed/37202259
http://dx.doi.org/10.1016/j.neurol.2023.01.727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186396/
https://www.ncbi.nlm.nih.gov/pubmed/37202259
http://dx.doi.org/10.1016/j.neurol.2023.01.727

Ejemplares similares